Patients must be enrolled on ANBLB or APECB prior to enrollment on ANBL
Patients must be enrolled within  year after diagnosis
Patients must be enrolled on AALLB or APECB (if available for ALL patients) prior to enrollment on AALL
Patients must be enrolled on ALTEC prior to enrollment on ACNS\r\n* Patients must be enrolled within  days of definitive diagnostic surgery (day )\r\n** Note: patients must begin treatment within  days of definitive surgery
For patients enrolled on AALLB or APECB (if open for ALL patients) prior to enrollment on AALL, the required diagnostic bone marrow sample has been fulfilled\r\n* For patients who have not previously enrolled on AALLB or APECB (if open for ALL patients) prior to enrollment on AALL, a baseline diagnostic sample must be available to develop an MRD probe\r\n* In addition, laboratory reports detailing evidence of BCR-ABL fusion must be submitted for rapid central review within  hours of study enrollment
The use of hormonal therapy is not allowed; if the patient in on a -alpha reductase inhibitor, then they should be stopped prior to treatment once enrolled onto the study; no washout period is required for this study to participate
Patients must be enrolled before treatment begins; the date protocol therapy is to start must be no later than  days from the time of recurrence and within  days from enrollment
For Phase , only subjects HER or HER molecular/genetic alterations will be enrolled.
Known prior severe hypersensitivity to platinum-related compounds for all cohorts, to pemetrexed for patients enrolled in Cohort A, and to gemcitabine for patients enrolled in Cohort A
Non-active hepatitis B (HBsAg-, Anti-HBs+, Anti-HBc+) may be enrolled at the discretion of the investigator after consideration of risk of reactivation.
Patients may not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy
The subject is fluent in the language as designated by the institution at which he would be enrolled.
Enrolled in another clinical trial testing a novel therapy or drug within the past  weeks.
Patients who have received acute, low-dose, systemic immunosuppressant medications may be enrolled
Patients excluded for laboratory abnormalities or performance score ONLY may be enrolled on the study with the approval of the PI or designee
Prior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be enrolled in group  and  in the dose expansion part. Exceptions may be made after documented agreement between Novartis and Investigator.
Unresectable disease. Patients with resectable disease may be enrolled after having refused surgery after a documented consultation with a surgeon.
Patients in remission who are enrolled on another study where time to progression or disease free survival is a primary endpoint
Patients may not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy; (Note: patients on the standard therapy arm of another GBM trial that otherwise meet eligibility requirements for this trial remains eligible for cohort )
Note: Patients may be enrolled more than once (e.g., for a new tumor)
Subjects must be co-enrolled on protocol -C- (Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).
The patient has previously been enrolled in the study or received ESK
The participant has received prior treatment with gemcitabine or docetaxel. Note: Participants previously enrolled in the IB-MC-JGDJ (NCT) or any other blinded study with olaratumab are not eligible to participate in this trial.
Currently enrolled in a clinical study.
Patient is receiving or plans to receive other investigational therapy and/or is enrolled or plans to enroll in a separate clinical study.
Patients must agree to participate in long-term follow-up for up to  years if they are enrolled in the study and receive T cell infusion
Any patients who cannot be compliant with the appointments required in this protocol must not be enrolled in this study.
Any patient who cannot be compliant with the appointments required in this protocol must not be enrolled in this study
Patient is or will be enrolled on protocol -CH-, Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma
Currently enrolled in another interventional study.
Previously enrolled in the present study
If you are pregnant, you will not be enrolled on this study
Currently enrolled in another clinical trial.
Patients who are simultaneously enrolled in any other treatment study
Any patients who cannot be compliant with the appointments required in this protocol must not be enrolled in this study
Currently enrolled in, or discontinued within the last  days from a clinical trial involving an investigational product or non-approved use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Patients must be enrolled on the trial within  weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy
Enrolled on another clinical trial testing a novel therapy or drug
In the first  patients enrolled in treatment groups on part B of this study (receiving combination ipilimumab and nivolumab), patients may have had - prior lines of systemic therapy after being diagnosed with metastatic disease; this restriction will be lifted in all subsequent cohorts of patients treated on part B
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
For subjects being enrolled to receive PLD plus carboplatin, prior treatment with anthracyclines or anthracenodiones
Subjects who screen fails can be re-enrolled if the causation of the screen fail has been corrected
Patients with multiple lesions, which by size criteria would be enrolled in a cohort which is full at the time of enrollment and the - week dose-limiting toxicity (DLT) period has not yet been reached
If organ dysfunction is thought to be related to the HLH process this must be clearly documented in the chart and the patients may be enrolled on study irrespective of creatinine and bilirubin levels
PART : Meeting criteria for st phase as above, at time of initiation of JAK inhibitor, including ability to understand and willingness to sign a written informed consent; patients arriving to our institution for transplant and not enrolled in Part  may still be enrolled in Part  if Part  criteria met; these patients will have Part  endpoints transcribed from medical records
Shares the same address as a currently enrolled participant
Any patients who cannot be compliant with the appointments required in this protocol must not be enrolled in this study
Patients who are simultaneously enrolled in any other treatment study
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Patients with a history of cancer that has been completely treated, with no evidence of malignant disease currently cannot be enrolled in the study if their chemotherapy was completed less than  months prior and/or have received a bone marrow transplant less than  years before the first day of study treatment
Urine dipstick positive (>+) for blood during screening with investigation indicating glomerular haematuria. If other causes are identified, subjects may be enrolled on resolution of the abnormality
Currently enrolled in Studies GS-US--, GS-US--, or GS-US--
Previously enrolled in this study.
Patients must be enrolled and protocol therapy must be projected to begin no later than  days after definitive diagnostic surgery (Day )
Previous or concurrent cancer that is distinct from tumor for which the patient is enrolled in study, with exceptions
Currently enrolled in a Valor-sponsored IGN study
RENAL & BLADDER: Currently enrolled in another interventional study
Only patients with tumors that score positive in the in vitro organoid bio-assay will be enrolled in the clinical trial; patients with tumors that score negative in this bio-assay will be considered screening failures and will not be enrolled in the clinical trial
T-ALL: T-ALL patients must be enrolled on AALLB or Project:EveryChild (APECB, if open for the classification of ALL patients) prior to treatment and enrollment on AALL
Patients must be enrolled on ALTEC prior to enrollment on ACNS; patients must be enrolled within  days of definitive diagnostic surgery (day ) or clinical diagnosis
FOR PATIENTS IN STAGE  (ENROLLED PATIENT # AND BEYOND)
Patients must be enrolled within  weeks following completion of therapy
Patients must be enrolled on study within  days of definitive surgical resection at which time tissue is acquired to determine a diagnosis; patients must be enrolled before treatment begins; the date protocol therapy is projected to start must be no later than five () calendar days after the date of study enrollment; patients who are started on protocol therapy on a Phase II study prior to study enrollment will be considered ineligible
No history of cardiomegaly or bilateral pulmonary infiltrates on chest radiograph or computed tomography (CT); however, patients with cardiomegaly on imaging may be enrolled if they have an assessment of cardiac function (i.e., echocardiography [ECHO] or multi gated acquisition scan [MUGA]) within  weeks of starting protocol therapy that is within normal limits; additionally, patients with bilateral pulmonary infiltrates on imaging may be enrolled if the lesions are not consistent with active neuroblastoma (i.e., negative on functional imaging with PET or MIBG, or by pathologic assessment)
If patient goes on to have an open thoracotomy as part of surgical treatment they will not be enrolled
Patients enrolled on another therapeutic study
Patients must be enrolled between  to  weeks post OLT
Patients enrolled after August ,  must be candidates for cytoreductive surgery and consent to have their surgical treatment determined by randomization
This criterion applies only to the patients enrolled before August ,  and those enrolled after this date electing to receive bevacizumab; patients must have a urine protein-to-creatinine ratio (UPCR) < . mg/dL
Subjects enrolled into the C Cohort must have not had treatment for their metastatic disease
If enrolled in Part SA, new, growing, or previously untreated lesions since the start of anti-PD- therapy.
Hepatitis B + patients may be enrolled at the discretion of the investigator
Currently enrolled in study CCLE, or YM-II-, or successfully completed  weeks of study GS-US--
Are currently enrolled in another clinical trial.
Patients who are currently enrolled on another clinical trial
Enrolled on another clinical trial testing a novel therapy or drug
For subjected enrolled in the United States, no coverage or not-acceptable by patient co-pay for lenalidomide
Are currently enrolled or discontinued less than  days from another clinical trial
Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a previously radiated field may be enrolled if it has been at least  weeks since the last dose of radiation therapy
A woman who is pregnant or breast feeding, or a man who plans to father a child while enrolled in this study or within  months after the last dose of study drug
No more than  prior chemotherapy regimens for metastatic disease for those in the dose escalation cohorts; prior trastuzumab and lapatinib are allowed for the HER+ population; once we reach the expanded recommended phase  dose (RPD) cohorts, patients enrolled must have received =<  prior regimens\r\n* Patients enrolled in ARM C may remain on trastuzumab without a washout period\r\n* Patients enrolled in ARM D may remain on lapatinib without a washout period
Exclusion criteria below (*) apply only to patients who are enrolled AFTER completing  to  cycles of first-line chemotherapy; exclusion criteria (*) DO NOT APPLY to patients who are enrolled prior to completing  to  cycles of first-line chemotherapy; these patients can be enrolled but ultimately MAY not be treated with radiation therapy/SBRT; this is dependent on their restaging imaging after the completion of chemotherapy
Subjects who screen fails can be re?enrolled if the causation of the screen fail has been corrected
Patients must be enrolled on the trial within  weeks of the later of two dates: the final breast conserving surgical procedure or administration of the last cycle of cytotoxic chemotherapy
Patients must have been enrolled, or agree to consent to the companion genomic profiling study MSKCC IRB# -; results must be available before starting treatment on protocol
Previously or currently enrolled in Protocol No. TPI--
Patients aged >=  are not excluded; however, candidates in this age group should be thoroughly evaluated before enrollment in the study, to ensure they are fit to receive chemotherapy, and to potentially undergo pancreaticoduodenectomy; in addition to meeting all of the baseline patient selection criteria, clinical judgment on their susceptibility to infection and expected stability of their performance status and suitability to receive intensive chemotherapy cycles, should be paid special attention to; patients should not be enrolled in the study should there be any hesitation on any of these considerations; baseline criteria for all patients enrolled on the study must be carefully evaluated and all criteria followed appropriately
Patients must have been enrolled, or agree to consent to the companion genomic profiling study MSKCC IRB# -
Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown
Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.
Was enrolled on the Phase  clinical trial ONT-- and:
Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST . criteria for solid tumors.
Patients who are eligible for HSCT but with non-optimal AML disease control (i.e., blasts > %) may be enrolled into this study as a bridge-to-transplant.
Are currently enrolled in, or discontinued within the last  days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Patients must be enrolled before treatment begins; the date protocol therapy is projected to start must be no later than ten () calendar days after the date of study enrollment; patients should be enrolled preferably between day  and day  after peripheral blood stem cell (PBSC) infusion (day from nd stem cell infusion for tandem transplant); patients must be enrolled no later than day  after PBSC infusion; enrollment must occur after completion of radiotherapy, and after completion of tumor assessment post-ASCT and radiotherapy; informed consent should be obtained within  weeks pre-ASCT up to the time of registration
Currently enrolled in another interventional study
Patients currently enrolled in another study; concurrent enrollment in another study is prohibited expect for the control arm which can be used for other protocols with HRQOL endpoints with similar instruments
Be planning to start yoga on their own during the time they are enrolled in the study
Another household member enrolled in the study
Currently already enrolled on the TrueNTH website
Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components
CHILD: Child understands English and is enrolled in school (but can be bilingual)
 Subject was previously enrolled in Study .
Subject has previously been enrolled in this study and received at least  per protocol PLT transfusion
Participants who develop treatment complications or disease recurrence after being enrolled in the study may continue to participate if they are able to do so
Patients currently enrolled onto therapeutic cancer clinical trial(s) involving non-standard cancer drugs
Patients currently enrolled on Children's Oncology Group (COG) study ACCL are not eligible until they have completed the infection observation period of that study
Patients previously enrolled on this trial are ineligible
Patients previously enrolled on the trial are not eligible; therefore, patients with AL who were on study during intensive chemotherapy are not eligible to be enrolled during the HSCT
Patients currently enrolled on the ACCL study are not eligible until they have completed the  day observation period of that study
Currently enrolled in a physical therapy course
Participants who develop treatment complications or disease recurrence after being enrolled in the study may continue to participate if they are able to do so
Patients enrolled on phase  of the study are eligible (and/or if recruited from tumor registry or clinic follow-up schedules)
Subjects must be already enrolled in P.R.O.G.E.C.T observational registry (HSC #)
Patients who are enrolled in another symptom management trial
Are enrolled in any other cancer prevention/outreach related study
enrolled in a competing study; and
FOR THE  SUBJECTS ENROLLED IN YEAR : If patients are on immunosuppressive therapy for treatment of GVHD, then only those on stable doses for at least  weeks (or on tapering doses) will be eligible
FOR THE  SUBJECTS ENROLLED IN YEAR : Pregnant female
BETA/USABILITY TESTING: Will have been enrolled for year prior to the mammogram at Group Health
Another household member being enrolled in the study.
Enrolled on Dana-Farber Cancer Institute (DFCI) protocol - or any other sun protection intervention in the past  years
Individuals enrolled in or who plan to enroll in a clinical intervention trial; there must be a -day period between completing a previous study and enrolling in this study; the principal investigator will have the option to consider an exception for patients on drugs of interest for the purpose of this study
Pregnant women are excluded from this study; patients enrolled in the study must be able to undergo intensive RT plus or minus chemotherapy
Another household member enrolled in the study
Currently enrolled at Salish Kootenai College
SUBJECTS ENROLLED IN THE TREATMENT GROUPS RECEIVING VACCINE ONLY (NOT THE IMIQUIMOD GROUP):
Currently enrolled on an interventional investigational study
Enrolled in a communication program (university student review)
Enrolled in th or th grade
No prior systemic therapy EXCEPT patients may be consented and enrolled if they have already started mFOLFIRINOX for up to four cycles
Currently enrolled as a first year Ohio State University (OSU) student on the Columbus campus
Another household member enrolled in the study
No patients with multicentric or multifocal disease scheduled to undergo multiple lumpectomies; multifocal disease that can be encompassed in a single operative bed can be enrolled; for patients with multifocal or multicentric disease enrolled after completion of neoadjuvant chemotherapy, histologic confirmation of multifocality/multicentricity must have been completed before initiation of chemotherapy
Participants who are already enrolled in a conflicting investigational trial
Enrolled in study part #
Patients who are not enrolled in the OCSP
Subjects may be enrolled at any point in diagnosis or treatment
Are enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study within  days of the initial dose of study drug.
Currently enrolled in protocol - (PCS study)